Trial reportCancer research communications2026
A Phase II Study of Berzosertib in Combination with Carboplatin Compared with Docetaxel with Carboplatin in Metastatic Castration-Resistant Prostate Cancer.
Trial report in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Synthetic lethality in cancer: mechanisms, therapeutic exploitation and clinical translation.Signal transduction and targeted therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
Abstract
purposeInhibitors of the ataxia-telangiectasia and Rad3-related (ATR) protein kinase, a critical component of the DNA damage repair response, have synergistic anticancer activity with platinum compounds in preclinical models. We therefore conducted a phase II study of the ATR inhibitor berzosertib + carboplatin versus docetaxel + carboplatin in metastatic castration-resistant prostate cancer (mCRPC). PATIENTS AND
methodsPatients previously treated with at least one androgen receptor pathway inhibitor and taxane underwent mandatory biopsy and were randomized 1:1 to receive arm A (docetaxel 60 mg/m2 + carboplatin AUC4 day 1 or carboplatin AUC5 if not a docetaxel candidate) or arm B (berzosertib 90 mg/m2 days 2 and 9 + carboplatin AUC5 day 1) every 21 days. The primary endpoint was overall response rate (ORR; ≥50% PSA decline or radiographic response).
resultsOf 73 randomized patients, 65 received protocol treatment: 34 on arm A (26 docetaxel + carboplatin and 8 carboplatin alone) and 31 on arm B. Thirteen patients (38%) in arm A and 20 (65%) in arm B had ≥ grade 3 treatment-related adverse events (TrAE). ORR was 15% in arm A [5/34; 5/26 (19%) with docetaxel + carboplatin] and 0% in arm B (0/31). At interim analysis, after 65 of the planned 130 patients were treated, enrollment was halted due to futility. Homologous recombination repair (HRR) deficiency status from tissue and blood did not correlate with clinical outcomes, but ATM deficiency or high levels of phospho-Krüppel-associated box (KRAB) domain-associated protein 1 (pKAP1) detected in tissue were associated with clinical benefit across both arms of the trial.
conclusionsBerzosertib + carboplatin demonstrated lower ORR and more frequent ≥ grade 3 TrAEs compared with docetaxel + carboplatin in this heavily pretreated, biomarker-unselected population. SIGNIFICANCE: The combination of the ATR inhibitor berzosertib with carboplatin demonstrated a lower ORR compared with docetaxel with carboplatin in a heavily pretreated biomarker-unselected mCRPC population. Assays for HRR deficiency showed limited predictive capability, but a combined tissue biomarker of ATM deficiency and elevated pKAP1 (indicating elevated replication stress) was associated with benefit in both study arms and warrants investigation for benefit from carboplatin-based therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.